Cognition Therapeutics Inc Dossier - Source-backed chat

Cognition Therapeutics Inc

CGTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.53

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.89Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $84.7M

Enterprise Value $50.9M

Shares Outstanding 100.5M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cognition Therapeutics is a high-potential, clinical-stage biopharmaceutical company targeting neurodegenerative diseases through its lead candidate, zervimesine (CT1812). By targeting the sigma-2 receptor to displace toxic protein oligomers, zervimesine offers a unique, orally available mechanism distinct from traditional amyloid-clearing antibodies. Following positive Phase 2 SHIMMER data in dementia with Lewy bodies (DLB) showing an 86% improvement in behavioral outcomes, the company has pivoted to prioritize DLB psychosis as its primary registrational path. Backed by substantial non-dilutive NIH/NIA grant funding and a cash runway extending into Q2 2027, Cognition presents an attractive risk-reward profile for investors seeking exposure to late-stage neurodegenerative catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.50

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The FDA requires extensive, multi-year Phase 3 trials for DLB psychosis, delaying commercialization timelines. Furthermore, the Phase 2 START trial in early Alzheimer's disease fails to show statistically significant cognitive benefits or safety issues emerge, severely damaging the clinical viability of zervimesine. The company's cash runway is depleted faster than expected, forcing highly dilutive equity offerings at depressed valuations.

Base CaseCentral scenario

$3.3350%

Cognition successfully initiates a Phase 2b/3 registrational study in DLB psychosis following positive FDA feedback. The Phase 2 START trial in early Alzheimer's disease completes on schedule with positive topline results in 2027, confirming zervimesine's disease-modifying potential. The company utilizes its ATM facility and strategic capital raises to maintain a stable balance sheet, gradually re-rating toward consensus analyst targets as clinical milestones are achieved.

Bull CaseUpside scenario

$4.0030%

The FDA aligns on a rapid, single Phase 3 registrational trial path for zervimesine in DLB psychosis, leading to accelerated approval. Concurrently, the Phase 2 START trial in early Alzheimer's disease reads out highly positive topline data in 2027, demonstrating strong synergy when combined with background antibody therapies (e.g., lecanemab). This triggers a lucrative global co-development partnership with a major pharmaceutical company, fully funding late-stage clinical trials and driving substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated oral small-molecule mechanism targeting the sigma-2 receptor to displace toxic amyloid-beta and alpha-synuclein oligomers.
Strong Phase 2 proof-of-concept data in DLB (SHIMMER) showing significant improvements in neuropsychiatric, cognitive, and motor symptoms.
Substantial non-dilutive funding with nearly $200 million in cumulative NIH/NIA and related foundation grants, reducing capital intensity and shareholder dilution.
Strategic pivot to DLB psychosis, an indication with high unmet medical need and no FDA-approved disease-modifying therapies.

Key Investment Risks

High binary clinical trial risk typical of early-stage central nervous system (CNS) drug development.
Single-asset dependency on zervimesine (CT1812) for near-to-mid-term commercial success.
Capital constraints, requiring additional dilutive equity raises or partnerships to fund large-scale Phase 3 trials beyond Q2 2027.

Thesis Invalidation Triggers

Failure of the Phase 2 START trial in early Alzheimer's disease to meet its primary cognitive or biomarker endpoints.
Regulatory roadblocks from the FDA Division of Psychiatry regarding the registrational path for DLB psychosis.
Severe safety or tolerability signals emerging in ongoing clinical trials or expanded access programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.